Radiotherapy quality assurance in the TROG 12.01 randomised trial and its impact on loco-regional failure

- Corry, June, Moore, Alisha, Mcdowell, Lachlan, Wilkinson, Dean, Tiong, Albert, Rischin, Danny, Kenny, Liz, Wratten, Chris, Fua, Tsien, Lin, Charles, Porceddu, Sandro, Liu, Chen, Ruemelin, Michael, Sharkey, Amy

Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus–Associated Oropharyngeal Cancer: A TROG 12.01 Secondary Analysis

- McDowell, Lachlan, Bressel, Mathias, King, Madeleine T., Corry, June, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Rischin, Danny

Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study

- Rischin, Danny, King, Madeleine, Fua, Tsien, Lin, Charles, Liu, Chen, Hughes, Brett G. M., McGrath, Margaret, McDowell, Lachlan, Corry, June, Kenny, Lizabeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Bressel, Mathias, Herschtal, Alan, Fisher, Richard

Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study

- Young, Richard J., Solomon, Benjamin, Rischin, Danny, Corry, June, Angel, Christopher, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Herschtal, Alan